Application of 17alpha estradiol or chemically modified derivative thereof in preparation of medicine for preventing and / or treating male hypogonadism
By using 17α estradiol or its chemically modified derivatives, the serum testosterone and Gnrh levels in aged male mice have been enhanced, and the side effects and limited efficacy of existing drugs have been solved, providing new therapeutic options and having longevity function, significantly improving The therapeutic effect.
Patent Information
- Application Number
- CN202411226622.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing drugs for treating hypogonadal function in men, such as testosterone replacement therapy and hormone drugs, have side effects and limited efficacy, and are difficult to simulate the pulse secretion characteristics of hormones in the human body, resulting in poor treatment effect and expensive. inconvenient.
Using 17α estradiol or its chemically modified derivatives, by changing the solubility and target affinity of drug molecules, it is used to prepare drugs to prevent and treat male hypogonadism, significantly enhance serum testosterone and Gnrh levels in aged male mice.
It significantly enhances serum testosterone and Gnrh levels in older male mice, provides new treatment options, and has life-extended functions, increasing the drug's promotion potential in the elderly population.
Smart Images

Figure CN119055659A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of 17α-estradiol or its chemically modified derivatives in the preparation of drugs for preventing and / or treating male hypogonadism. Background Art
[0002] Hypogonadism caused by age factors is called late-onsethypogonadism, which is characterized by low androgen levels. It has a great impact on the normal physiology and psychology of men, and seriously affects the patient's health level and quality of life. For example, the disease can cause mental symptoms such as fatigue, muscle weakness, decreased cognitive ability, inattention, sensitivity, forgetfulness, irritability, anxiety, depression, and vasomotor disorder symptoms such as fever, restlessness, and sweating. These symptoms have certain similarities with women's menopausal syndrome, and the disease is also called male menopause (andropause).
[0003] At present, testosterone replacement therapy is used clinically to treat late-onset hypogonadism. Although it has a certain therapeutic effect, long-term use of the drug often causes many side effects such as prostate hyperplasia, prostate cancer, uncontrollable congestive heart failure, severe lower urinary tract dysfunction and polycythemia. In addition, human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG) and gonadotropin-releasing hormone (Gnrh) can also be used to treat such diseases. These hormones in the human body show the characteristics of pulsatile secretion. Clinical medication cannot effectively simulate the characteristics of pulsatile secretion, and the efficacy is limited. In addition, long-term use of the drug will also lead to a decrease in target gonadal receptors, reduce sensitivity, and make medication cumbersome. Although the Gnrh analog infusion pump that simulates pulsatile secretion has a good effect, it is expensive and inconvenient to use. Therefore, the prevention and treatment of such senile diseases requires continuous exploration and enrichment of the types of therapeutic drugs and treatment methods.
[0004] Estradiol has two natural isomers, namely α-estradiol and β-estradiol. Among them, 17β-estradiol has high hormonal activity and is the main female hormone in the body. 17α-estradiol is also a natural hormone in the body. Because it has only weak estrogenic activity and relatively weak binding to natural estrogen receptors, it is called non-feminizing estrogen. Its main function in the human body is still unclear, but 17α-estradiol can improve metabolic activity, enhance insulin sensitivity, reduce fat and anti-inflammatory functions in elderly mice, and can significantly prolong the lifespan of male elderly mice after long-term feeding. What's more peculiar is that the life-extending function of this hormone only exists in male animals and is ineffective in females. The specific mechanism is unknown. Summary of the invention
[0005] In view of the deficiencies of the prior art, the present invention provides the use of 17α-estradiol or its chemically modified derivatives in the preparation of a drug for preventing and / or treating male hypogonadism. 17α-estradiol can significantly enhance the serum testosterone and Gnrh levels of aged male mice.
[0006] The present invention is achieved through the following technical solutions:
[0007] Application of 17α-estradiol or its chemically modified derivatives in the preparation of drugs for preventing and / or treating male hypogonadism.
[0008] Preferably, the chemical modification is a modification aimed at changing the solubility of the drug molecule and / or its affinity to the target.
[0009] Preferably, the male is a middle-aged or elderly male.
[0010] Preferably, the drug further comprises a pharmaceutically acceptable carrier.
[0011] Preferably, the dosage form of the drug is any pharmaceutically therapeutically acceptable dosage form.
[0012] A pharmaceutical composition for preventing and / or treating male hypogonadism comprises 17α-estradiol or a chemically modified derivative thereof.
[0013] The beneficial effects of the present invention are as follows:
[0014] The present invention discovered through experiments that 17α-estradiol can significantly enhance the serum testosterone and Gnrh levels of aged male rats. This discovery adds new drug options for the prevention and treatment of sexual dysfunction in aged men. In addition, the life-extending function of the drug increases the potential for the drug to be promoted and used in the elderly population in the future, and has a good prospect for promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The effects of 17α-estradiol on male rat gonadal function in Example 1: A is the effect of 17α-estradiol on the bioavailable testosterone level of aged male brown Norwegian rats; B is the effect of 17α-estradiol on the estrogen level of aged male brown Norwegian rats; C is the effect of 17α-estradiol on the Gnrh level of aged male brown Norwegian rats; the dot-bar structure in the figure is the mean ± SD, the number indicated is the P value, and the statistical method is a two-tailed unpaired T test;
[0016] Figure 2 The effects of 17α-estradiol on the anti-inflammatory function and reproductive toxicity of male rats in Example 1: A is the anti-inflammatory function of male rats, the dot-bar structure in the figure is the mean ± SD, the marked number is the P value, and the statistical method is a two-tailed unpaired T test; B is the HE-stained section of the testis of aged male rats. DETAILED DESCRIPTION
[0017] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0018] Unless otherwise specified, the technical means used in the following examples are all conventional means well known to those skilled in the art, and the experimental methods without specifying the specific conditions are all conventional methods in the art.
[0019] The experimental animals used in the following examples were purchased from Beijing Weitonglihua.
[0020] In the present invention, the term "prevention" means a method of preventing the onset of a disease and / or its attendant symptoms or protecting a subject from acquiring a disease. "Prevention" as used herein also includes delaying the onset of a disease and / or its attendant symptoms and reducing the risk of a subject acquiring a disease.
[0021] In the present invention, the term "treatment" includes delaying and stopping the progression of the disease, or eliminating the disease, and does not require 100% inhibition, elimination and reversal.
[0022] Example 1
[0023] The English name of 17α-estradiol: 17α-estradiol, Chinese alias: 17a-estradiol, 1,3,5(10)estradiol-3,17α-diol, molecular formula: C 18 H 24 O2, molecular weight: 272.38200, CAS number: 57-91-0, structural formula is as follows:
[0024]
[0025] 1. Experimental steps
[0026] Male brown Norwegian rats purchased from Beijing Weitonglihua were divided into 3 groups, 4 rats in each group. The young group (Y) was 4 months old, the old group (O) and the old group (OT) fed with 17α-estradiol were 30 months old. The OT group was fed with 17α-estradiol feed for 6 months from 24 months old. 17α-estradiol was added to the rat feed at a ratio of 14.4 mg / kg. All rats in the groups were fed with conventional feeding (12h light and 12h dark-proof feeding) and free access to food.
[0027] Serum was collected from each group of rats between 9:00 and 9:30 in the morning, and the content of Gnrh, estradiol and bioavailable testosterone was determined by competitive enzyme-linked immunosorbent assay (ELISA). At the same time, the testicles of male rats in the aged group were removed for formaldehyde fixation, paraffin embedding, sectioning and HE staining. The calculation of the inflammatory index was based on whether the seminiferous tubules collapsed, atrophied and sperm count, with inflammation as 1 and normal as 0. There were 8 testicles in each group, and the seminiferous tubules of each testicle under 10× and 20× microscopes were statistically plotted.
[0028] 2. Experimental results
[0029] like Figure 1 As shown in Figure 2, continuous feeding of 17α-estradiol for 6 months could significantly reverse and increase the serum bioavailable testosterone level of 30-month-old brown Norway rats (OT group) ( Figure 1 A) and Gnrh levels ( Figure 1 C), significantly reducing the estrogen level in aged rats ( Figure 1 (B).
[0030] like Figure 2 As shown in B, the left picture is a normal non-inflammatory OT testis HE staining section, with normal seminiferous tubule structure and normal sperm morphology; the right picture is an aged testis HE staining section after inflammatory infiltration, with severe seminiferous tubule collapse, which is an aging inflammatory reaction. Figure 2 It can be seen that long-term feeding of 17α-estradiol did not cause damage to the testicles ( Figure 2 B), but slightly reduced testicular inflammation in aged rats ( Figure 2 (A, P = 0.15).
[0031] The embodiments described above are only some embodiments of the present invention, rather than all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. The scope of protection of the present invention shall be subject to the scope required by the claims. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work shall fall within the scope of protection of the present invention.
Claims
1. Use of 17α-estradiol or its chemically modified derivatives in the preparation of drugs for preventing and / or treating male hypogonadism.
2. The use according to claim 1, characterized in that: The chemical modification is aimed at changing the solubility of the drug molecule and / or its affinity to the target.
3. The use according to claim 1, characterized in that: The male is a middle-aged or elderly male.
4. The use according to claim 1, characterized in that: The medicament further includes a pharmaceutically acceptable carrier.
5. The use according to claim 1, characterized in that: The dosage form of the drug is any pharmaceutically therapeutically acceptable dosage form.
6. A pharmaceutical composition for preventing and / or treating male hypogonadism, characterized in that: Including 17α estradiol or its chemically modified derivatives.
Citation Information
Patent Citations
Traditional Chinese medicine composition with effects of delaying male gonad axis recession and resisting oxidation and inflammatory injury as well as preparation method and application of traditional Chinese medicine composition
CN115887592A
Pharmaceutical preparation containing steroid having antioxidant action and used as substitute for drug hormone in man
JP1997100292A
Estradiol-containing drug delivery system
US20110097405A1
Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases
US5855905A
USE OF 17- alpha -ESTRADIOL FOR THE TREATMENT OF AGED OR SUNDAMAGED SKIN AND / OR SKIN ATROPHY
WO1999008654A1
